Pharma Mar SA (ES:PHM)
BME:PHM
Want to see ES:PHM full AI Analyst Report?
PHM Stock Chart & Stats
€97.35
€0.65(0.83%)
At close: 4:00 PM EST
€97.35
€0.65(0.83%)
Day’s Range― - ―
52-Week Range€70.10 - €105.20
Previous CloseN/A
Volume4.24K
Average Volume (3M)74.16K
Market Cap
€1.71B
Enterprise Value€1.73B
Total Cash (Recent Filing)€167.85M
Total Debt (Recent Filing)€47.54M
Price to Earnings (P/E)20.6
Beta0.87
Next Earnings
Aug 05, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend Yield1.04%
Share Statistics
EPS (TTM)4.65
Shares Outstanding18,000,000
10 Day Avg. Volume71,270
30 Day Avg. Volume74,161
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.12
Price to Sales (P/S)5.82
P/FCF Ratio29.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€120.50Price Target Upside23.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.63
Revenue Forecast (FY)€228.29M
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained high TTM gross and net margins indicate durable pricing power or low incremental COGS for marketed oncology products. High margins support internal R&D funding, buffer trial setbacks, and improve long-term cash available for reinvestment or partner deals, strengthening strategic optionality.
Strong Revenue ReboundA large, recent revenue rebound signals successful commercial traction or milestone recognition from the company’s therapies and partnerships. If maintained, this expands recurring sales base and improves predictability of royalty/licensing income, underpinning multi-quarter operational stability.
Conservative LeverageLow debt-to-equity provides financial flexibility to fund ongoing trials, commercial rollouts, or absorb regulatory delays without urgent refinancing. Conservative leverage reduces solvency risk and preserves capacity for strategic investments or partnerships over the medium term.
Bears Say
Through-cycle VolatilityHistorical swings from weakness to strong results show earnings and cash can be highly cyclical for this biotech. This structural volatility complicates forecasting, increases financing risk in down cycles, and can force strategic trade-offs between R&D spend and cash preservation.
Inconsistent Cash ConversionOCF materially below accounting earnings and past negative FCF indicate profits do not always convert to stable cash. This raises the likelihood of intermittent external funding or milestone-dependent inflows, limiting the company’s ability to steadily self-fund growth and R&D over multiple quarters.
Dependency On Clinical/regulatory MilestonesRevenue and cash timing hinge on trial results, approvals, and partner milestones—structural risks for a biotech. Delays or negative outcomes can defer milestones and royalties, producing sustained revenue shortfalls and making long-term planning and steady revenue growth more uncertain.
Pharma Mar SA News
PHM FAQ
What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was €70.10 and its highest was €105.20 in the past 12 months.
What is Pharma Mar SA’s market cap?
Pharma Mar SA’s market cap is €1.71B.
When is Pharma Mar SA’s upcoming earnings report date?
Pharma Mar SA’s upcoming earnings report date is Aug 05, 2026 which is in 63 days.
How were Pharma Mar SA’s earnings last quarter?
Pharma Mar SA released its earnings results on Apr 23, 2026. The company reported €0.088 earnings per share for the quarter, beating the consensus estimate of €0.008 by €0.08.
Is Pharma Mar SA overvalued?
According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued.
Does Pharma Mar SA pay dividends?
Pharma Mar SA pays a Annually dividend of €0.8 which represents an annual dividend yield of 1.04%. See more information on Pharma Mar SA dividends here
What is Pharma Mar SA’s EPS estimate?
Pharma Mar SA’s EPS estimate is 0.18.
How many shares outstanding does Pharma Mar SA have?
Pharma Mar SA has 18,000,000 shares outstanding.
What happened to Pharma Mar SA’s price movement after its last earnings report?
Pharma Mar SA reported an EPS of €0.088 in its last earnings report, beating expectations of €0.008. Following the earnings report the stock price went up 3.083%.
Which hedge fund is a major shareholder of Pharma Mar SA?
Currently, no hedge funds are holding shares in ES:PHM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharma Mar SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€120.50 (23.78% Upside)
€120.50 (23.78% Upside)
Insider Transactions
Bought Shares
Worth €10.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.08%
12-Months-Change
Fundamentals
Return on Equity
35.74%
Trailing 12-Months
Asset Growth
23.22%
Trailing 12-Months
Company Description
Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
PHM Company Deck
PHM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.View all ES:PHM earnings summariesPHM Stock 12 Month Forecast
Average Price Target
€120.50
▲(23.78% Upside)
Technical Analysis
Laboratorios Farmaceuticos Rovi
―
Oryzon Genomics SA
―
―
1nKemia IUCT Group SA
―
Atrys Health SA
―
Options Prices
Currently, No data available
---